Skip to main content
Caplight Logo









CDR-Life

CDR-Life

Private
HorgenHealthcare & Life Scienceshttps://www.cdr-life.com/

Last Round

Series A

Apr 13, 2022

Total Funding Raised

$88.7M

Company Overview

CDR-Life is a biotechnology company that develops tumor-selective immunotherapies using its proprietary M-gager® antibody technology to target intracellular antigens for cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyantibody therapeuticsdrug discoveryoncologyT-cell engagertrispecific antibodysolid tumor treatmentbiopharmaantibody engineeringimmunotherapyclinical developmentdrug licensingbiotech platformcancer research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CDR-Life Comparables

Compare CDR-Life with similar companies based on industry and business-model similarity.

CDR-Life comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Clasp Therapeutics
81%
Gilead Sciences
81%
EvolveImmune Therapeutics
81%

CDR-Life Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 13, 2022
SeedMay 11, 2021

Key People

Founding team and executive leadership

Christian Leisner

Co-Founder & CEO

Founding Team

Rouven Bingel-Erlenmeyer

Chief Technology Officer

Executive Team

Konstantin von Schulthess

Chief Financial Officer

Executive Team

CDR-Life Investors

Notable investors and investment history

CDR-Life investors
InvestorRounds
RA Capital ManagementSeries A
Omega FundsSeries A
Jeito CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 3, 2026

    Dimitrios Chondros appointed as the new Chief Medical Officer.

  • Nov 4, 2025

    Global licensing agreement for trispecific antibody CDR111 with Boehringer Ingelheim.

CDR-Life Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CDR-Life Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CDR-Life's valuation, stock price, and market status.

Firmographic Details

HeadquartersHorgen
Employee Range70
Year Founded2017
Last FundingApr 13, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?